Trial Profile
A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Anacetrapib (Primary) ; Atorvastatin
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 01 Sep 2017 Results (n=12) of a substudy assessing mechanism by which CETP inhibition reduces Lp(a) published in the Arteriosclerosis Thrombosis and Vascular Biology
- 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
- 09 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.